FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity

Application Seeks to Extend Use of BOTOX® for Patients 5 to 17 Years Old NORTH CHICAGO, Ill., June 22, 2020 -- (Healthcare Sales & Marketing Network) -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administr... Biopharmaceuticals, Neurology, FDA Allergan, AbbVie, BOTOX, onabotulinumtoxinA, Neurogenic Detrusor Overactivity

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2046111

Source: HSMN NewsFeed - June 22, 2020 Category: Pharmaceuticals Source Type: news